another is running a razor thin edge on financing,

Quote:

---

another is running a razor thin edge on financing, which caught up to them a month ago and hurt the share price.

---

If there is an expectation of a rise in share price that strategy is fine. Anyone who has done extensive due diligence would have that expectation. NP knowing he was in talks and until he was double sandbagged by the FDA in February and August would have that same expectation.

Even prior to that who would have thought the FDA would have not accepted the great results in the Phase 3 interventional monotherapy trial.